Prurigo Nodularis Treatment Market Report 2026

Prurigo Nodularis Treatment Market Overview

• Prurigo Nodularis Treatment market size has reached to $1.72 billion in 2025 • Expected to grow to $2.2 billion in 2030 at a compound annual growth rate (CAGR) of 5% • Growth Driver: Surge In Chronic Skin Conditions Fueling The Growth Of The Market Due To Increasing Exposure To Environmental Pollutants • Market Trend: Advancements In Monoclonal Antibody Therapies For Prurigo Nodularis Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Prurigo Nodularis Treatment Market?

Prurigo nodularis treatment involves various medical approaches designed to alleviate the persistent itching and skin lesions associated with this inflammatory condition. The main objective is to interrupt the cycle of scratching that exacerbates the symptoms. Treatment aims to soothe itching, promote healing of nodules, and enhance the patient’s overall well-being. The main types of prurigo nodularis treatment include medication, cryotherapy, phototherapy, pulsed dye laser, and others. Medications are substances used to reduce itching, inflammation, and modulate the immune response. It is diagnosed using skin biopsy, blood tests, and others, and is administered through several administration routes, including topical administration, oral administration, and parenteral administration. It is distributed through various distribution channels such as hospital pharmacies, retail pharmacies, and online pharmacies, and is utilized by several end-users, including clinics, hospitals, and others.

What Is The Prurigo Nodularis Treatment Market Growth Forecast?

The prurigo nodularis treatment market size is expected to see steady growth in the next few years. It will grow to $2.2 billion in 2030 at a compound annual growth rate (CAGR) of 5.0%. The growth in the forecast period can be attributed to increasing approvals of novel biologics, rising investments in dermatology R&D, expanding use of precision medicine approaches, growing demand for long-term symptom control, increasing adoption of advanced laser-based therapies. Major trends in the forecast period include increasing adoption of biologic therapies, rising focus on targeted anti-inflammatory treatments, growing use of combination therapy approaches, expansion of advanced phototherapy techniques, enhanced emphasis on patient-centric treatment protocols.

Global Prurigo Nodularis Treatment Market Segmentation

1) By Treatment: Medication, Cryotherapy, Phototherapy, Pulsed Dye Laser, Other Treatments 2) By Diagnosis: Skin Biopsy, Blood Tests, Other Diagnosis 3) By Route Of Administration: Topical Administration, Oral Administration, Parenteral Administration 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 5) By End-Users: Clinic, Hospital, Other End-Users Subsegments: 1) By Medication: Topical Corticosteroids, Antihistamines, Immunosuppressants, Neuromodulators, Biologic Therapies 2) By Cryotherapy: Liquid Nitrogen Application, Spray-Freezing Techniques, Cryoprobe Therapy 3) By Phototherapy: Narrowband Ultraviolet B (NB-UVB), Broadband Ultraviolet B (BB-UVB), Psoralen Plus Ultraviolet A (PUVA) 4) By Pulsed Dye Laser: 585 Nanometer (nm) Wavelength Therapy, 595 Nanometer (nm) Wavelength Therapy 5) By Other Treatments: Behavioral Therapy, Psychological Itch Management Programs, Emollients and Moisturizers, Surgical Excision

What Is The Driver Of The Prurigo Nodularis Treatment Market?

The rising incidence of chronic skin conditions is expected to propel the growth of the prurigo nodularis treatment market going forward. Chronic skin conditions refer to long-lasting or recurring skin disorders that often require ongoing management and can significantly affect a person's quality of life. The increase in chronic skin conditions is rising due to greater exposure to environmental pollutants, which can damage the skin's natural barrier and cause prolonged inflammation. Prurigo nodularis treatment addresses the root causes of chronic skin conditions by targeting the inflammatory pathways responsible for persistent itching and skin lesions. By regulating the immune system's overactivity, these therapies effectively relieve symptoms and enhance the quality of life for those with chronic prurigo nodularis. For instance, in July 2023, according to the Office of Health Economics (OHE), a UK-based registered charity, hidradenitis suppurativa (HS), a painful chronic skin disease, affects at least 200,000 people in the UK, and the economic impact of hidradenitis suppurativa is estimated to be around £3.83 ($4.35) billion annually. Therefore, the rising incidence of chronic skin conditions is driving the growth of the prurigo nodularis treatment industry.

Key Players In The Global Prurigo Nodularis Treatment Market

Major companies operating in the prurigo nodularis treatment market are Roche Holding AG, Sanofi S.A., Amgen Inc., Regeneron Pharmaceuticals Inc., Galderma S.A, Incyte Corporation, LEO Pharma A/S, Almirall S.A., Maruho Co. Ltd., VYNE Therapeutics Inc., Kiniksa Pharmaceuticals Ltd., Trevi Therapeutics Inc., Keymed Biosciences Inc., Shanghai SIGMA High-tech Co. Ltd., Celgene Corporation, Celldex Therapeutics Inc., Pfizer Inc., Eli Lilly And Company, AbbVie Inc., Johnson And Johnson, Bristol Myers Squibb, Novartis AG, AstraZeneca PLC

Global Prurigo Nodularis Treatment Market Trends and Insights

Major companies operating in the prurigo nodularis treatment market are focused on developing advanced therapies, such as monoclonal antibodies, to target specific immune pathways and provide more effective relief from symptoms. Monoclonal antibodies are laboratory-made molecules designed to mimic the immune system's ability to fight off harmful pathogens, such as viruses. For instance, in August 2024, Galderma, a Switzerland-based pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved Nemluvio (nemolizumab) as a treatment for adult patients with prurigo nodularis. The approval was based on positive results from the OLYMPIA clinical trials, where Nemluvio demonstrated significant improvement in itch intensity and skin nodules. This treatment specifically targets IL-31 signaling, addressing a key factor driving prurigo nodularis symptoms.

What Are Latest Mergers And Acquisitions In The Prurigo Nodularis Treatment Market?

In November 2025, Sanofi S.A., a France-based biopharmaceutical company involved in prurigo nodularis treatment, partnered with Regeneron Pharmaceuticals Inc. to develop the biologic therapy Dupixent, which achieved all primary and secondary endpoints in a pivotal study for allergic fungal rhinosinusitis. The partnership aims to speed up therapeutic innovation by uniting complementary scientific strengths and advanced biologic development capabilities. Regeneron Pharmaceuticals Inc. is a US-based biotechnology company.

Regional Outlook

North America was the largest region in the prurigo nodularis treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Prurigo Nodularis Treatment Market?

The prurigo nodularis treatment market consists of revenues earned by entities by providing services such as medical consultation, psychological support, wound care, and bandaging. The market value includes the value of related goods sold by the service provider or included within the service offering. The prurigo nodularis treatment market also includes sales of patch test kits, punch biopsy tools, and injectable monoclonal antibodies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Prurigo Nodularis Treatment Market Report 2026?

The prurigo nodularis treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the prurigo nodularis treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.